Results 1 to 10 of about 1,998,403 (289)

Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis

open access: yesBrazilian Journal of Oncology, 2022
Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events.
Maria Paula Furtado Santos   +9 more
doaj   +2 more sources

Perioperative immune-checkpoint inhibitors for muscle-invasive bladder cancer [PDF]

open access: yesDrugs in Context
Muscle-invasive bladder cancer (MIBC) has a high risk of recurrence following radical cystectomy. Neoadjuvant cisplatin-based chemotherapy has been used for decades to lower recurrence rates but a significant proportion of patients still have disease ...
Albert Jang   +6 more
doaj   +2 more sources

Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review [PDF]

open access: yesIntestinal Research, 2023
Immune checkpoint inhibitors have dramatically revolutionized the therapeutic landscape for patients with advanced malignancies. Recently, convincing evidence has shown meaningful influence of gut microbiome on human immune system.
Sung Wook Hwang   +2 more
doaj   +1 more source

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities

open access: yesFrontiers in Oncology, 2022
Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of hepatocellular carcinoma over the past few years.
Qingqing Xie   +4 more
doaj   +1 more source

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?

open access: yesFrontiers in Immunology, 2022
Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian   +5 more
doaj   +1 more source

Research Advances in Intracranial Radiotherapy Combined with Immune Checkpoint Inhibitors on Lung Cancer Brain Metastasis

open access: yesZhongliu Fangzhi Yanjiu, 2020
In recent years, immunotherapy has been continuously developed, and the safety and efficacy of immune checkpoint inhibitors combined with intracranial radiotherapy for melanoma brain metastasis have been initially recognized.
HE Qian, REN Qinglan
doaj   +1 more source

Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series

open access: yesJournal for ImmunoTherapy of Cancer, 2019
Background In non-small cell lung cancer, response rates to chemotherapy given after immune checkpoint inhibitors has been reported to be higher compared to response rates to chemotherapy given before immune checkpoint inhibitors.
Rayan Alsuwaigh   +4 more
doaj   +1 more source

Pneumonitis and multiple pneumonial infections under combined immune‐checkpoint inhibition

open access: yesJEADV Clinical Practice, 2023
The introduction of immune checkpoint inhibitors and targeted therapies has revolutionized melanoma treatment. The downside are immune‐mediated adverse events which are frequent and require close patient management.
Kristine E. Mayer   +4 more
doaj   +1 more source

Challenges of Immune Checkpoint Inhibitors in Treatment of Non-small Cell Lung Cancer

open access: yesZhongliu Fangzhi Yanjiu, 2019
With the gradually in-depth research of immune checkpoint, the checkpoint inhibitors, such as programmed death-1(PD-1) inhibitors, programmed death–ligand 1(PD-L1) inhibitors and cytotoxic T lymphocyte-associated protein-4(CTLA-4) inhibitors, had made ...
LI Xiangmin, FAN Zaiwen
doaj   +1 more source

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

open access: yesFrontiers in Cell and Developmental Biology, 2020
Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/
Minjeong Yeon   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy